Amgen Inc. Outstanding Bonds
Note series still outstanding, nearest maturity first. Terms are from each offering's final pricing term sheet on SEC EDGAR; a reopening of the same CUSIP adds to its principal. Interest per payment = principal × coupon ÷ payments per year. Outstanding = principal issued minus each filed exchange, tender, redemption or conversion; it is (m) where the retired amount was not filed. Interest per payment uses the outstanding principal.
- 2.200% Senior Notes due 2027: Principal issued $750.00M; Outstanding $750.00M; Coupon 2.20%; Trade date 2020-02-18.
- 3.200% Senior Notes due 2027: Principal issued $1.00B; Outstanding $1.00B; Coupon 3.20%; Trade date 2017-10-31.
- 5.150% Senior Notes due 2028: Principal issued $3.75B; Outstanding $3.75B; Coupon 5.15%; Trade date 2023-02-15.
- 1.650% Senior Notes due 2028: Principal issued $1.25B; Outstanding $1.25B; Coupon 1.65%; Trade date 2021-08-05.
| Notes | Principal issued | Outstanding | Coupon | Trade date | Issue / settlement date | Maturity date | Interest payment dates | Interest per payment | Annual coupon interest | Optional redemption | Retired | Priced |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.200% Senior Notes due 2027 CUSIP (m) | $750.00M | $750.00M | 2.20% | 2020-02-18 | 2020-02-21 | 2027-02-21 | Semi-annually: February 21, August 21 | $8.25M | $16.50M | 2020-02-18 | ||
| 3.200% Senior Notes due 2027 CUSIP 031162CQ1 · US031162CQ15 | $1.00B | $1.00B | 3.20% | 2017-10-31 | 2017-11-02 | 2027-11-02 | Semi-annually: November 2, May 2 | $16.00M | $32.00M | 2017-10-31 | ||
| 5.150% Senior Notes due 2028 CUSIP (m) | $3.75B | $3.75B | 5.15% | 2023-02-15 | 2023-03-02 | 2028-03-02 | Semi-annually: March 2, September 2 | $96.56M | $193.13M | 2023-02-16 | ||
| 1.650% Senior Notes due 2028 CUSIP 031162DB3 · US031162DB37 | $1.25B | $1.25B | 1.65% | 2021-08-05 | 2021-08-09 | 2028-08-15 | Semi-annually: February 15, August 15 | $10.31M | $20.63M | 2021-08-06 | ||
| 3.000% Senior Notes due 2029 CUSIP 031162DD9 · US031162DD92 | $750.00M | $750.00M | 3.00% | 2022-02-17 | 2022-02-22 | 2029-02-22 | Semi-annually: February 22, August 22 | $11.25M | $22.50M | 2022-02-17 | ||
| 4.050% Senior Notes due 2029 CUSIP 031162DH0 · US031162DH07 | $1.25B | $1.25B | 4.05% | 2022-08-15 | 2022-08-18 | 2029-08-18 | Semi-annually: February 18, August 18 | $25.31M | $50.63M | 2022-08-15 | ||
| 2.450% Senior Notes due 2030 CUSIP (m) | $1.25B | $1.25B | 2.45% | 2020-02-18 | 2020-02-21 | 2030-02-21 | Semi-annually: February 21, August 21 | $15.31M | $30.63M | 2020-02-18 | ||
| 5.250% Senior Notes due 2030 CUSIP (m) | $2.75B | $2.75B | 5.25% | 2023-02-15 | 2023-03-02 | 2030-03-02 | Semi-annually: March 2, September 2 | $72.19M | $144.38M | 2023-02-16 | ||
| 4.200% Senior Notes due 2031 CUSIP 031162DV9 · US031162DV90 | $1.00B | $1.00B | 4.20% | 2026-02-17 | 2026-02-19 | 2031-02-19 | Semi-annually: February 19, August 19 | $21.00M | $42.00M | 2026-02-17 | ||
| 2.000% Senior Notes due 2032 CUSIP (m) | $1.25B | $1.25B | 2.00% | 2021-08-05 | 2021-08-09 | 2032-01-15 | Semi-annually: January 15, July 15 | $12.50M | $25.00M | 2021-08-06 | ||
| 3.350% Senior Notes due 2032 CUSIP (m) | $1.00B | $1.00B | 3.35% | 2022-02-17 | 2022-02-22 | 2032-02-22 | Semi-annually: February 22, August 22 | $16.75M | $33.50M | 2022-02-17 | ||
| 4.200% Senior Notes due 2033 CUSIP (m) | $750.00M | $750.00M | 4.20% | 2022-08-15 | 2022-08-18 | 2033-03-01 | Semi-annually: March 1, September 1 | $15.75M | $31.50M | 2022-08-15 | ||
| 5.250% Senior Notes due 2033 CUSIP (m) | $4.25B | $4.25B | 5.25% | 2023-02-15 | 2023-03-02 | 2033-03-02 | Semi-annually: March 2, September 2 | $111.56M | $223.13M | 2023-02-16 | ||
| 4.850% Senior Notes due 2036 CUSIP (m) | $1.75B | $1.75B | 4.85% | 2026-02-17 | 2026-02-19 | 2036-02-19 | Semi-annually: February 19, August 19 | $42.44M | $84.87M | 2026-02-17 | ||
| 6.400% Senior Notes due 2039 CUSIP 031162BA7 · US031162BA71 | $1.00B | $1.00B | 6.40% | 2009-01-13 | 2009-01-16 | 2039-02-01 | Semi-annually: February 1, August 1 | $32.00M | $64.00M | 2009-01-14 | ||
| 3.150% Senior Notes due 2040 CUSIP (m) | $1.25B | $1.25B | 3.15% | 2020-02-18 | 2020-02-21 | 2040-02-21 | Semi-annually: February 21, August 21 | $19.69M | $39.38M | 2020-02-18 | ||
| 5.75% Senior Notes due 2040 CUSIP 031162BC3 · US031162BC38 | $700.00M | $700.00M | 5.75% | 2010-03-09 | 2010-03-12 | 2040-03-15 | Semi-annually: March 15, September 15 | $20.13M | $40.25M | 2010-03-10 | ||
| 2.800% Senior Notes due 2041 CUSIP (m) | $1.15B | $1.15B | 2.80% | 2021-08-05 | 2021-08-09 | 2041-08-15 | Semi-annually: February 15, August 15 | $16.10M | $32.20M | 2021-08-06 | ||
| 4.95% Senior Notes due 2041 CUSIP 031162BE9 · US031162BE93 | $600.00M | $600.00M | 4.95% | 2010-09-13 | 2010-09-16 | 2041-10-01 | Semi-annually: October 1, April 1 | $14.85M | $29.70M | 2010-09-14 | ||
| 5.15% Senior Notes due 2041 CUSIP 031162BK5 · US031162BK53 | $2.25B | $2.25B | 5.15% | 2011-11-07 | 2011-11-10 | 2041-11-15 | Semi-annually: May 15, November 15 | $57.94M | $115.88M | 2011-11-08 | ||
| 5.65% Senior Notes due 2042 CUSIP 031162BH2 · US031162BH25 | $1.25B | $1.25B | 5.65% | 2011-06-27 | 2011-06-30 | 2042-06-15 | Semi-annually: June 15, December 15 | $35.31M | $70.63M | Make-Whole: The 2042 notes will be redeemable, in whole at any time or in part from time to time, at the Issuer’s option | 2011-06-28 | |
| 5.600% Senior Notes due 2043 CUSIP (m) | $2.75B | $2.75B | 5.60% | 2023-02-15 | 2023-03-02 | 2043-03-02 | Semi-annually: March 2, September 2 | $77.00M | $154.00M | 2023-02-16 | ||
| 5.375% Senior Notes due 2043 CUSIP 031162BP4 · US031162BP41 | $1.00B | $1.00B | 5.38% | 2012-05-10 | 2012-05-15 | 2043-05-15 | Semi-annually: May 15, November 15 | $26.88M | $53.75M | 2012-05-11 | ||
| 4.400% Senior Notes due 2045 CUSIP 031162BZ2 · US031162BZ23 | $1.25B | $1.25B | 4.40% | 2015-04-28 | 2015-05-01 | 2045-05-01 | Semi-annually: May 1, November 1 | $27.50M | $55.00M | 2015-04-29 | ||
| 5.500% Senior Notes due 2046 CUSIP (m) | $500.00M | $500.00M | 5.50% | 2026-02-17 | 2026-02-19 | 2046-02-19 | Semi-annually: February 19, August 19 | $13.75M | $27.50M | 2026-02-17 | ||
| 3.375% Senior Notes due 2050 CUSIP (m) | $1.25B | $1.25B | 3.38% | 2020-02-18 | 2020-02-21 | 2050-02-21 | Semi-annually: February 21, August 21 | $21.09M | $42.19M | 2020-02-18 | ||
| 3.000% Senior Notes due 2052 CUSIP (m) | $1.35B | $1.35B | 3.00% | 2021-08-05 | 2021-08-09 | 2052-01-15 | Semi-annually: January 15, July 15 | $20.25M | $40.50M | 2021-08-06 | ||
| 4.200% Senior Notes due 2052 CUSIP (m) | $1.00B | $1.00B | 4.20% | 2022-02-17 | 2022-02-22 | 2052-02-22 | Semi-annually: February 22, August 22 | $21.00M | $42.00M | 2022-02-17 | ||
| 4.875% Senior Notes due 2053 CUSIP (m) | $1.00B | $1.00B | 4.88% | 2022-08-15 | 2022-08-18 | 2053-03-01 | Semi-annually: March 1, September 1 | $24.38M | $48.75M | 2022-08-15 | ||
| 5.650% Senior Notes due 2053 CUSIP (m) | $4.25B | $4.25B | 5.65% | 2023-02-15 | 2023-03-02 | 2053-03-02 | Semi-annually: March 2, September 2 | $120.06M | $240.13M | 2023-02-16 | ||
| 5.650% Senior Notes due 2056 CUSIP (m) | $750.00M | $750.00M | 5.65% | 2026-02-17 | 2026-02-19 | 2056-02-19 | Semi-annually: February 19, August 19 | $21.19M | $42.38M | 2026-02-17 | ||
| 4.400% Senior Notes due 2062 CUSIP (m) | $1.25B | $1.25B | 4.40% | 2022-02-17 | 2022-02-22 | 2062-02-22 | Semi-annually: February 22, August 22 | $27.50M | $55.00M | 2022-02-17 | ||
| 5.750% Senior Notes due 2063 CUSIP (m) | $2.75B | $2.75B | 5.75% | 2023-02-15 | 2023-03-02 | 2063-03-02 | Semi-annually: March 2, September 2 | $79.06M | $158.13M | 2023-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |